Addimmune
HIV-focused gene/cell therapy business spun out of American Gene Technologies; a SPAC merger with 10X Capital Venture Acquisition Corp. III was announced Aug 2023 targeting a Q1 2024 close, but SEC EDGAR shows no completed rename/relisting under the shell company CIK as of this check, and no live quote exists for the reported ticker HIV on any exchange -- treated as still private/merger-not-confirmed-closed rather than trusting secondary press coverage.
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
AGT103-TNo recent activity | Phase 1 | HIV proviral reservoir / autologous T cellsGene therapy / editing | HIV |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.